GlassScriptPhysician profile
Todd W Lester
NPI 1528009537
$4,983.52
in general payments reported to CMS, 2019-2025
38 companies · $659 in 2025
The $659 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,323 · 2022: $518 · 2023: $990 · 2024: $1,495 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,143.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $752.97 | 2021-2025 | |
| Lilly USA, LLC | $613.68 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $527.05 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $485.36 | 2021-2025 | Farxiga, Lokelma, Tezspire |
| Esperion Therapeutics, INC. | $405.24 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $307.49 | 2021-2025 | Camzyos, Eliquis |
| Glaxosmithkline, LLC. | $303.69 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $143.27 | 2021-2022 | |
| Shield Therapeutics INC | $135.73 | 2023-2024 | Accrufer |
| Paratek Pharmaceuticals, INC. | $130.78 | 2024-2025 | Nuzyra |
| Teva Pharmaceuticals USA, INC. | $101.74 | 2021-2022 | |
| Dexcom, INC. | $91.38 | 2023-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $91.25 | 2021-2023 | |
| Amgen INC. | $89.97 | 2021-2025 | Evenity, Tezspire, Repatha |
| Otsuka America Pharmaceutical, INC. | $86.58 | 2022-2024 | Jynarque |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Lester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.